Xantis Pharma acquires portfolio and teams up with Saneca for manufacturing and R&D

Xantis Pharma has acquired more than 20 pharmaceutical products and has signed a five-year manufacturing and development contract with Slovakia-based CDMO Saneca Pharmaceuticals.

The 20 products will be marketed by Xantis Pharma, leveraging the company’s marketing reach and knowledge with focus on Russia, Ukraine, CEE and CIS countries.

Xantis Pharma now has marketing operations in 5 countries, Russia, Kazakhstan, Ukraine, Czech and Slovakia with headquarters in Zug, Switzerland.

Grigory Chudakov, Chief Commercial Officer at Xantis Pharma, said: 'By combining our strong market presence in Central and Eastern Europe with Saneca Pharma’s strengths in drug development and manufacturing, we are confident that we can expand the reach of the 20 pharmaceutical products that have transferred to our portfolio.'

The two companies also committed to develop nine new products in coming three years, with Saneca leading development and Xantis promoting new offerings through its marketing channels.